home / stock / pali / pali quote
Last: | $4.35 |
---|---|
Change Percent: | -4.19% |
Open: | $4.7 |
Close: | $4.54 |
High: | $4.7 |
Low: | $4.35 |
Volume: | 11,257 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.35 | $4.7 | $4.54 | $4.7 | $4.35 | 11,257 | 07-03-2024 |
$4.54 | $4.3 | $4.54 | $4.5699 | $4.3 | 8,180 | 07-02-2024 |
$4.3 | $4.72 | $4.3 | $4.72 | $4.3 | 16,419 | 07-01-2024 |
$4.5 | $4.57 | $4.5 | $4.57 | $4.4401 | 7,675 | 06-28-2024 |
$4.57 | $4.5201 | $4.57 | $4.6 | $4.5 | 9,974 | 06-27-2024 |
$4.58 | $4.69 | $4.58 | $4.763 | $4.52 | 12,638 | 06-26-2024 |
$4.47 | $4.64 | $4.47 | $4.83 | $4.47 | 26,588 | 06-25-2024 |
$4.62 | $4.71 | $4.62 | $4.76 | $4.51 | 26,328 | 06-24-2024 |
$4.81 | $4.67 | $4.81 | $4.81 | $4.67 | 28,387 | 06-21-2024 |
$4.76 | $4.65 | $4.76 | $5.15 | $4.59 | 56,094 | 06-20-2024 |
$4.69 | $4.57 | $4.69 | $4.9999 | $4.5201 | 31,692 | 06-19-2024 |
$4.69 | $4.57 | $4.69 | $4.9999 | $4.5201 | 31,692 | 06-18-2024 |
$4.68 | $4.55 | $4.68 | $4.68 | $4.46 | 6,864 | 06-17-2024 |
$4.64 | $4.5 | $4.64 | $4.64 | $4.32 | 27,415 | 06-14-2024 |
$4.54 | $4.58 | $4.54 | $4.58 | $4.42 | 6,300 | 06-13-2024 |
$4.46 | $4.49 | $4.46 | $4.6 | $4.42 | 15,950 | 06-12-2024 |
$4.49 | $4.67 | $4.49 | $4.67 | $4.4 | 34,171 | 06-11-2024 |
$4.61 | $4.62 | $4.61 | $4.62 | $4.44 | 15,026 | 06-10-2024 |
$4.57 | $4.77 | $4.57 | $4.77 | $4.55 | 7,203 | 06-07-2024 |
$4.69 | $4.58 | $4.69 | $4.73 | $4.453 | 38,598 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel...
– Collaboration advancing Palisade Bio’s precision medicine approach through access to cutting-edge expertise and tools in bioinformatics – Candidate PDE4-related biomarkers overlapping with UC pathophysiology have been identified and innovative selection strategy dev...
PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end Carlsbad, CA, June 11, 2024 (GLOBE NEWSWIRE) -- Palisad...